The board of Medivir AB says it wants to complete the division of the company into two publicly listed companies by the end of 2016, as the Swedish biotech continues to work on a strategy to cope with declining royalties from its hepatitis C protease inhibitor, simeprevir.
A separate listing of a so-far unnamed commercial company on First North Premium, NASDAQ’s European market of smaller by fast-growing...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

